# Laura J. Esserman

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/laura-j-esserman/

## Facts

| Field | Value |
| --- | --- |
| Citations | 34,110 |
| Field | Breast Cancer Treatment Studies |
| h-index | 91 |
| i10-index | 364 |
| Last Known Institution | University of California, San Francisco |
| OpenAlex ID | https://openalex.org/A5072789687 |
| ORCID iD | 0000-0001-9202-4568 |
| Works | 982 |

## Researcher papers

Showing 12 of 21.

- [Genomic and transcriptional aberrations linked to breast cancer pathophysiologies](https://scholariq.org/papers/genomic-and-transcriptional-aberrations-linked-to-breast-cancer/)
- [Whole-genome analysis informs breast cancer response to aromatase inhibition](https://scholariq.org/papers/whole-genome-analysis-informs-breast-cancer-response-to-aromatase-inhibition/)
- [Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial](https://scholariq.org/papers/risk-adapted-targeted-intraoperative-radiotherapy-versus-whole-breast/)
- [Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial](https://scholariq.org/papers/targeted-intraoperative-radiotherapy-versus-whole-breast-radiotherapy-for-breast/)
- [Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer](https://scholariq.org/papers/effect-of-pembrolizumab-plus-neoadjuvant-chemotherapy-on-pathologic-complete/)
- [Breast Cancer Follow-Up and Management After Primary Treatment: American Society of Clinical Oncology Clinical Practice Guideline Update](https://scholariq.org/papers/breast-cancer-follow-up-and-management-after-primary-treatment-american-society/)
- [Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031](https://scholariq.org/papers/randomized-phase-ii-neoadjuvant-comparison-between-letrozole-anastrozole-and/)
- [Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-veliparib-carboplatin-treatment-in-breast-cancer/)
- [Rethinking Screening for Breast Cancer and Prostate Cancer](https://scholariq.org/papers/rethinking-screening-for-breast-cancer-and-prostate-cancer/)
- [Addressing overdiagnosis and overtreatment in cancer: a prescription for change](https://scholariq.org/papers/addressing-overdiagnosis-and-overtreatment-in-cancer-a-prescription-for-change/)
- [Adaptive Randomization of Neratinib in Early Breast Cancer](https://scholariq.org/papers/adaptive-randomization-of-neratinib-in-early-breast-cancer/)
- [Personalized early detection and prevention of breast cancer: ENVISION consensus statement](https://scholariq.org/papers/personalized-early-detection-and-prevention-of-breast-cancer-envision-consensus/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Breast Lesions and Carcinomas](https://scholariq.org/topics/breast-lesions-and-carcinomas/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Researcher university

- [University of California, San Francisco](https://scholariq.org/institutions/university-of-california-san-francisco/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.